

**AMENDMENTS TO THE CLAIMS**

1-68. (Canceled)

69. (Currently Amended) A monoclonal antibody or fragment thereof that binds to human mannose binding lectin (MBL)~~The antibody or fragment thereof of claim 63~~, wherein the monoclonal antibody is produced by hybridoma cell line 3F8 deposited under ATCC Accession No. HB-12621.

70. (Currently Amended) A monoclonal antibody or fragment thereof that binds to human mannose binding lectin (MBL)~~The antibody or fragment thereof of claim 63~~, wherein the monoclonal antibody is produced by hybridoma cell line 2A9 deposited under ATCC Accession No. HB-12620.

71. (Currently Amended) A monoclonal antibody or fragment thereof that binds to human mannose binding lectin (MBL)~~The antibody or fragment thereof of claim 63~~, wherein the monoclonal antibody is produced by hybridoma cell line hMBL1.2 deposited under ATCC Accession No. HB-12619.

72-79. (Canceled)

80. (Previously Presented) A hybridoma cell line 3F8 deposited under ATCC Accession No. HB-12621.

81. (Previously Presented) A hybridoma cell line 2A9 deposited under ATCC Accession No. HB-12620.

82. (Previously Presented) A hybridoma cell line hMBL1.2 deposited under ATCC Accession No. HB-12619.

83. (Previously Presented) A composition comprising:  
an antibody or fragment thereof that binds to human MBL, wherein the antibody is produced by hybridoma cell line 3F8 deposited under ATCC Accession No. HB-12621, hybridoma cell line 2A9 deposited under ATCC Accession No. HB-12620 or hybridoma cell line hMBL1.2 deposited under ATCC Accession No. HB-12619, and a pharmaceutically acceptable carrier.

84. (Previously Presented) The composition of claim 83, wherein the antibody or fragment thereof is in an amount effective to treat an MBL mediated disorder.

85. (Previously Presented) The composition of claim 83, further comprising a drug for the treatment of an MBL mediated disorder.

86. (Previously Presented) The composition of claim 83, wherein the fragment is an F(ab')<sub>2</sub> fragment, an Fab fragment, an Fv fragment or an Fd fragment.

87-92. (Canceled)

93. (Previously Presented) An antibody or fragment thereof that binds to human MBL, wherein the antibody is produced by hybridoma cell line 3F8 deposited under ATCC Accession No. HB-12621, hybridoma cell line 2A9 deposited under ATCC Accession No. HB-12620, or hybridoma cell line hMBL1.2 deposited under ATCC Accession No. HB-12619.